PRIMARY STUDY
Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia
Key Findings: In patients with chronic renal failure and anemia the group treated with epoetin had decreased urinary liver-type fatty-acid-binding protein (L-FABP) levels compared with the untreated group.
Type of Study: Clinical Trial
Study Sample Size: 20
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2006
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Nakamura T, et al. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia. Am J Nephrol. 2006; 26:276-80. doi: 10.1159/000093934
Authors: Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H
